BR112021020846A2 - Regimes de dosagem para e composições incluindo anticorpos anti-rsv - Google Patents

Regimes de dosagem para e composições incluindo anticorpos anti-rsv

Info

Publication number
BR112021020846A2
BR112021020846A2 BR112021020846A BR112021020846A BR112021020846A2 BR 112021020846 A2 BR112021020846 A2 BR 112021020846A2 BR 112021020846 A BR112021020846 A BR 112021020846A BR 112021020846 A BR112021020846 A BR 112021020846A BR 112021020846 A2 BR112021020846 A2 BR 112021020846A2
Authority
BR
Brazil
Prior art keywords
dosage regimens
compositions including
including anti
rsv
rsv antibodies
Prior art date
Application number
BR112021020846A
Other languages
English (en)
Portuguese (pt)
Inventor
Ahmed Khan Anis
Vadryn Pierre
Original Assignee
Medimmune Ltd
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Sanofi Pasteur Inc filed Critical Medimmune Ltd
Publication of BR112021020846A2 publication Critical patent/BR112021020846A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
BR112021020846A 2019-04-30 2020-04-30 Regimes de dosagem para e composições incluindo anticorpos anti-rsv BR112021020846A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Publications (1)

Publication Number Publication Date
BR112021020846A2 true BR112021020846A2 (pt) 2022-01-18

Family

ID=70779897

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020846A BR112021020846A2 (pt) 2019-04-30 2020-04-30 Regimes de dosagem para e composições incluindo anticorpos anti-rsv

Country Status (15)

Country Link
US (3) US12024553B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962940A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022531205A (cg-RX-API-DMAC7.html)
KR (1) KR20220002427A (cg-RX-API-DMAC7.html)
CN (1) CN113825767A (cg-RX-API-DMAC7.html)
AU (1) AU2020265676A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021020846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014370A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192776A1 (cg-RX-API-DMAC7.html)
IL (1) IL287443A (cg-RX-API-DMAC7.html)
MX (1) MX2021013248A (cg-RX-API-DMAC7.html)
SG (1) SG11202111748TA (cg-RX-API-DMAC7.html)
TW (1) TWI861099B (cg-RX-API-DMAC7.html)
WO (1) WO2020223435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20240055097A (ko) * 2021-09-13 2024-04-26 메디뮨 리미티드 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방
EP4588936A4 (en) * 2022-12-08 2026-08-12 Changchun Bcht Biotechnology Co ANTIBODIES THAT BIND SPECIFICALLY TO VRS
CN121846262A (zh) * 2026-01-05 2026-04-14 上海生物制品研究所有限责任公司 抗呼吸道合胞病毒单克隆抗体制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤

Also Published As

Publication number Publication date
TW202106333A (zh) 2021-02-16
MX2021013248A (es) 2022-01-24
WO2020223435A1 (en) 2020-11-05
EP3962940A1 (en) 2022-03-09
CA3138180A1 (en) 2020-11-05
JP2025072444A (ja) 2025-05-09
IL287443A (en) 2021-12-01
US20220204593A1 (en) 2022-06-30
US12024553B2 (en) 2024-07-02
EA202192776A1 (ru) 2022-01-19
US20200347120A1 (en) 2020-11-05
KR20220002427A (ko) 2022-01-06
US20240417447A1 (en) 2024-12-19
CN113825767A (zh) 2021-12-21
JP2022531205A (ja) 2022-07-06
AU2020265676A1 (en) 2021-11-18
CO2021014370A2 (es) 2021-10-29
TWI861099B (zh) 2024-11-11
SG11202111748TA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112021007902A2 (pt) Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
CY1123211T1 (el) Meθοδoi γia th θepaπeytikh antimetωπισh ή thn προληψη thς hmikpaniaς
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
MX348579B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA202092460A1 (ru) Антитела к ox40 и способы применения
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
BR112019003989A2 (pt) métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
EA202192776A1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
BR112016028043A2 (pt) composições farmacêuticas, e transportador farmaceuticamente aceitável e anticorpo monoclonal para igg3 humana ou humanizada
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
BR112021006223A2 (pt) regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112019011350A2 (pt) terapia de combinação
BR112022003884A2 (pt) Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii
BR112019006994A2 (pt) uso médico de conjugado de fármaco citotóxico com anticorpo anti-c met
MX2023010764A (es) Anticuerpo anti componente del complemento 1s (c1s).
BR112022001546A2 (pt) Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]